Investigation The Relashinship Between Hashimoto Disease and TPOA in Patients’ Women
DOI:
https://doi.org/10.51699/cajmns.v7i2.3212Keywords:
Anti-thyroid peroxidase (anti-TPO) antibodies, Hashimoto disease, biomarkers, hypothyroidismAbstract
Background; Hashimoto thyroiditis is an autoimmune illness that destroys thyroid cells through cell and antibody-mediated immunological mechanisms. In developed countries, it causes most hypothyroidism. However, iodine deficiency is the leading cause of hypothyroidism worldwide. Hashimoto thyroiditis is caused by antithyroid antibodies attacking thyroid tissue, creating fibrosis. The diagnosis might be difficult; hence the disease is occasionally identified late. Most lab tests show elevated thyroid-stimulating hormone (TSH), decreased thyroxine (T4), and enhanced antithyroid peroxidase (anti-TPO) antibodies. This exercise discusses Hashimoto thyroiditis' pathogenesis, diagnosis, and treatment, as well as the interprofessional team's role. Methodology: The study comprised 50 women with Hashimoto thyroditis, as well as a control group of 46 healthy, the patient and control who came to teaching Hospital between September 2022 and April 2023 in Basrah, Southern Iraq. TPA was measured using an Automated enzyme-linked fluorescence immunoassay (ELFA). Thyroid hormone (FT3, FT4, and TSH) was also measured using an Automated enzyme-linked fluorescence immunoassay (ELFA). Results; TPOA levels were significantly higher in patients compared to age-matched healthy controls, and FT4 and FT3 and levels were significantly lower in Hashimoto thyroiditis patients compared to age-matched healthy controls, according to the current study. Instead, and TSH are increased. Conclusions: From our results, we can conclude the relashinship between TPOA levels and Hashimoto thyroditis disease in women in Basra Governorate.
References
C. V. Preuss, A. Kalava, and K. C. King, StatPearls. Treasure Island, FL, USA: StatPearls Publ., 2021.
R. Oughtred et al., “The BioGRID interaction database: 2019 update,” Nucleic Acids Res., vol. 47, no. D1, pp. D529–D541, 2019.
B. Williams et al., “2018 ESC/ESH guidelines for the management of arterial hypertension,” Eur. Heart J., vol. 39, no. 33, pp. 3021–3104, 2018.
M. Ralli et al., “Hashimoto’s thyroiditis: An update on pathogenic mechanisms and management,” Autoimmun. Rev., vol. 19, no. 10, p. 102649, 2020.
W.-H. Chen, J. Yang, L. Guo, and S. Li, “Disturbance-observer-based control and related methods,” IEEE Trans. Ind. Electron., vol. 63, no. 2, pp. 1083–1095, 2015.
I. C. Nettore et al., “The molecular causes of thyroid dysgenesis: A systematic review,” J. Endocrinol. Investig., vol. 36, pp. 654–664, 2013.
A. T. Assaf et al., “Technical aspects of sphenopalatine ganglion microstimulator insertion,” Int. J. Oral Maxillofac. Surg., vol. 45, no. 2, pp. 245–254, 2016.
R. H. Haberman et al., “Methotrexate hampers immunogenicity to COVID-19 vaccine,” Ann. Rheum. Dis., vol. 80, no. 10, pp. 1339–1344, 2021.
Y. Gao et al., “Selective flotation of scheelite from calcite,” Int. J. Miner. Process., vol. 154, pp. 10–15, 2016.
A. K. C. Leung and A. A. C. Leung, “Evaluation and management of the child with hypothyroidism,” World J. Pediatr., vol. 15, pp. 124–134, 2019.
H. E. Menke and J. J. van Everdingen, “The practice guideline ‘vitiligo’,” Ned. Tijdschr. Geneeskd., vol. 150, no. 36, pp. 1976–1981, 2006.
T. H. Brix et al., “Monozygotic twins discordant for Hashimoto’s thyroiditis,” Autoimmunity, vol. 44, no. 3, pp. 188–194, 2011.
D. E. Williams et al., “Thyroid peroxidase as an autoantigen,” Horm. Metab. Res., vol. 50, no. 12, pp. 908–921, 2018.
M. Liu, E. Murphy, and E. H. Amerson, “Screening for thyroid autoimmunity in vitiligo,” J. Am. Acad. Dermatol., vol. 75, no. 6, pp. 1278–1280, 2016.
S. M. McLachlan and B. Rapoport, “The molecular biology of thyroid peroxidase,” Endocr. Rev., vol. 13, no. 2, pp. 192–206, 1992.
Y. Kohno et al., “Anti-thyroid peroxidase antibodies in sera,” Clin. Exp. Immunol., vol. 85, no. 3, pp. 459–463, 1991.
T. I. M. Korevaar, “Euthyroid thyroperoxidase antibody positivity during pregnancy,” Endocrinol. Metab., vol. 37, no. 3, pp. 387–391, 2022.
F. S. Balucan, S. A. Morshed, and T. F. Davies, “Thyroid autoantibodies in pregnancy,” J. Thyroid Res., 2013.
G. A. Carvalho et al., “Clinical use of thyroid function tests,” Arq. Bras. Endocrinol. Metabol., vol. 57, pp. 193–204, 2013.
J. Ginsberg, “Diagnosis and management of Graves’ disease,” CMAJ, vol. 168, no. 5, pp. 575–585, 2003.
P. Laurberg et al., “TSH-receptor autoimmunity in Graves’ disease,” Eur. J. Endocrinol., vol. 158, no. 1, pp. 69–75, 2008.
S. Mariotti et al., “Antithyroid peroxidase autoantibodies in thyroid diseases,” J. Clin. Endocrinol. Metab., vol. 71, no. 3, pp. 661–669, 1990.
M. Schmidt et al., “Long-term follow-up of antithyroid peroxidase antibodies,” Thyroid, vol. 18, no. 7, pp. 755–760, 2008.
E. Fröhlich and R. Wahl, “Thyroid autoimmunity and antibodies,” Front. Immunol., vol. 8, p. 521, 2017.
M. Godlewska et al., “Thyroid peroxidase revisited,” Horm. Metab. Res., vol. 51, no. 12, pp. 765–769, 2019.
L. J. DeGroot, “The non-thyroidal illness syndrome,” Endotext, 2015.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Haneen Sayar, Alaa Abdalhusein Saleh , Dawood Salman Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
